Access resources that may help you manage your chronic ITP treatment
How PROMACTA May Help
PROMACTA
PROMACTA
Have other treatments, such as steroids or intravenous immunoglobulin (IVIg), not worked to keep your platelet levels stable or have they caused too many side effects?
PROMACTA® (eltrombopag) may be an option to treat your chronic immune thrombocytopenia (chronic ITP). Once-daily PROMACTA can quickly boost your platelet counts and keep them stable over time.
PROMACTA has been studied extensively in more people with chronic ITP than any other drug of its kind, including 3 clinical trials for adults and 1 long-term study that lasted 7 years. More than 700 adults were enrolled in 3 separate studies, and 302 of them went on to participate in the long-term study, which was the longest and largest ever run in chronic ITP.
Did you know PROMACTA is also proven to work for children with chronic ITP as young as 1 year old? Go here to learn about PROMACTA for chronic ITP in children.
PROMACTA may help you reach your platelet goal
The proof is in the clinical studies of adults with chronic ITP.
In a clinical trial of 117 adults with chronic ITP...
PROMACTA works fast:



In a clinical trial of 302 adults with chronic ITP...
PROMACTA keeps working:

Other ways PROMACTA may help:

- At Day 15, PROMACTA showed a 64% reduction in serious bleeding vs placebo, from 22% to 8%
- At 1 year, PROMACTA showed a 76% reduction in serious bleeding vs placebo, from 17% to 4%
- 34 of 101 people who received additional medications permanently stopped taking at least 1 ITP medication, usually steroids
- At 5 years, in questionnaires used in the long-term trial, 80% of people with chronic ITP self-reported less fatigue, bleeding, and bruising
A wide range of people with chronic ITP were included in these clinical studies.
Data from 3 clinical studies and 1 long-term study of PROMACTA |
|
% of Males |
31-39% |
% of Females |
61-69% |
Median Age |
47-50 years old |
Average Starting |
Less than 30,000/mcL |
Did you know? Chronic ITP affects women more than men at a rate of almost 2:1.
Extensively studied in ~900 people with chronic ITP (ages 1 to 85)

- 730 adults
- 159 children

In clinical trials, consistently proven across patient types, no matter their age, sex, race, starting platelet count, number of medications they are taking for their ITP, or whether or not they’ve had their spleen removed
PROMACTA has demonstrated consistent safety, study after study
No other chronic ITP drug has been studied more than PROMACTA:
- The safety of PROMACTA was established in ~900 people, ranging in age from 1 to 85
- No single side effect occurred in more than 10% of people across 4 clinical studies
- PROMACTA may cause serious side effects including liver problems, blood clots, and cataracts
- The most common side effects of PROMACTA in adults and children include:
- low red blood cell count (anemia)
- nausea
- fever
- abnormal liver function tests
- cough
- tiredness
- headache
- diarrhea
- See additional safety information in the full Prescribing Information at https://www.novartis.us/sites/www.novartis.us/files/promacta.pdf
- At 6 years of treatment, no new or increased side effects were seen in comparison to the short-term trials
Now that you know PROMACTA has been proven to work for a wide range of people in clinical trials, find out how it works in your body to boost platelets. Click here.
What to expect when you’re starting PROMACTA
Learning how to make a new medicine part of your routine can take time. Each of the patients below had a different concern about starting treatment with PROMACTA. While everyone is unique, you may find it helpful to learn about other people’s experiences.
Take a look at the concerns below. Does anything sound familiar? See if something rings true for you.
Select each patient to learn more about his or her experience with taking PROMACTA.
The above are patient portrayals.
Being diagnosed with chronic ITP
Do you share any of the same thoughts or concerns as Carol, Tom, or Alice? Click here to read how other people have reacted to being told that they have chronic ITP.